Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease

Rohini Sidhu, Pamela Kell, Dennis J. Dietzen, Nicole Y. Farhat, An Ngoc Dang Do, Forbes D. Porter, Elizabeth Berry-Kravis, Charles H. Vite, Janine Reunert, Thorsten Marquardt, Roberto Giugliani, Charles M. Lourenço, Olaf Bodamer, Raymond Y. Wang, Ellen Plummer, Jean E. Schaffer, Daniel S. Ory, Xuntian Jiang

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Niemann-Pick type C (NPC) disease is a rare lysosomal storage disorder caused by mutations in either the NPC1 or the NPC2 gene. A new class of lipids, N-acyl-O-phosphocholineserines were recently identified as NPC biomarkers. The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-β-cyclodextrin (HPβCD) in NPC. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were developed and validated to measure PPCS in human plasma and cerebrospinal fluid (CSF). A cutoff of 248 ng/mL in plasma provided a sensitivity of 100.0% and specificity of 96.6% in identifying NPC1 patients from control and NPC1 carrier subjects. PPCS was significantly elevated in CSF from NPC1 patients, and CSF PPCS levels were significantly correlated with NPC neurological disease severity scores. Plasma and CSF PPCS did not change significantly in response to intrathetical (IT) HPβCD treatment. In an intravenous (IV) HPβCD trial, plasma PPCS in all patients was significantly reduced. These results demonstrate that plasma PPCS was able to diagnose NPC1 patients with high sensitivity and specificity, and to evaluate the peripheral treatment efficacy of IV HPβCD treatment.

Original languageEnglish
Pages (from-to)292-302
Number of pages11
JournalMolecular genetics and metabolism
Volume129
Issue number4
DOIs
StatePublished - Apr 2020

Keywords

  • 2-Hydroxypropyl-β-cyclodextrin
  • Diagnosis
  • LysoSM-509
  • N-palmitoyl-O-phosphocholineserine
  • Niemann-Pick disease type C
  • Treatment assessment

Fingerprint

Dive into the research topics of 'Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease'. Together they form a unique fingerprint.

Cite this